help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parfitt, A. M.
Right arrow Articles by Palnitkar, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parfitt, A. M.
Right arrow Articles by Palnitkar, S.
The Journal of Clinical Endocrinology & Metabolism Vol. 83, No. 3 863-869
Copyright © 1998 by The Endocrine Society


Original Studies

Rates of Cell Proliferation in Adenomatous, Suppressed, and Normal Parathyroid Tissue: Implications for Pathogenesis1

A. M. Parfitt, Q. Wang and S. Palnitkar

Bone and Mineral Division, Henry Ford Hospital, Detroit, Michigan 48202

Address all correspondence and requests for reprints to: A. M. Parfitt, M.D., Department of Endocrinology and Metabolism, University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot 587, Little Rock, Arkansas 72205-7199.


    Abstract
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
In previous studies, the birth rate of new cells in parathyroid adenomas measured at the time of surgical excision was shown to be much too low to account for growth of the tumors from a single cell in the time available, but comparison with normal rates was not possible. We measured the prevalence of cells expressing the Ki-67 antigen, a cell cycle marker, in 55 parathyroid adenomas using the MIB-1 antibody and microwave antigen retrieval; in 22 cases, separate measurements were made in nonadenomatous tissue from the same glands. In 10 cases complete maps of the gland profile were reconstructed to study the distribution of labeled cells. The proportion of Ki-67-positive cells, estimated by systematic random sampling, was used to calculate cell birth rate assuming a duration of Ki-67 expression of 24 h; the results were compared to rates previously determined in normal parathyroid glands by the same method. The geometric mean cell birth rate was 9.97%/yr, about double the normal rate of 5.4%/yr, but less than a third of the cases had values above the normal range. The corresponding value in nonadenomatous tissue was 2.58%/yr, about half the normal rate. In 10 cases studied in more detail, the cell birth rate was 12.3%/yr in the peripheral regions and 6.2%/yr in the central regions, a value not significantly different from normal. The results in adenomas are in reasonable agreement with previous estimates of cell birth rate of 13.7%/yr using [3H]thymidine labeling and 6.4%/yr using prevalence of the mitotic karyotype. The proportion of Ki-67-positive cells using unbiased sampling was about 50 times smaller than that in previous studies using selective sampling. Cell birth rates at the time of excision were about 20–25 times lower than initial rates estimated from modeling tumor growth by the Gompertz function. We conclude that 1) cell birth rate in parathyroid adenomas has fallen substantially during the growth of the tumors and is only modestly greater than normal; 2) the fall in cell birth rate had been greater in the central and presumably older regions of the adenoma than in the peripheral and presumably younger regions; 3) nonadenomatous tissue was suppressed with respect to its proliferative as well as its secretory function, presumably as a result of hypercalcemia; and 4) the progressive fall in cell birth rate, despite the accumulation of mutations that are supposed to increase cell birth rate, is most readily explained by the set-point hypothesis.


    Introduction
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
IN MOST patients with primary hyperparathyroidism discovered by multichannel biochemical screening, which is the most common manner of presentation in current practice, the clinical and biochemical course is nonprogressive (1), suggesting that by the time of diagnosis, the parathyroid tumor net growth rate has become very slow (2). Furthermore, the birth rate of new cells measured at the time of surgical excision is much too low to account for growth of the tumors from a single cell in the time available, indicating that cell birth rate must have declined substantially during the lifespan of the tumor (3, 4). In accordance with these observations, parathyroid cell proliferation and tumor growth as functions of time can be successfully modeled by the Gompertz function, with much closer approach to the asymptotic values than when this function is used to model the growth of malignant tumors (5).

Parathyroid adenoma cell birth rates measured by tritiated thymidine labeling (3) or by the prevalence of the mitotic karyotype (4) cannot be related to the rates in normal parathyroid tissue because the necessary data are unavailable. The Ki-67 antigen has a short half-life, labels only cycling cells (6), and with the MIB-1 antibody and microwave antigen retrieval can be applied to archival tissue (7). Using this method, we have recently reported a geometric mean cell birth rate for normal human parathyroid glands of about 5%/yr (8), demonstrating the parathyroid gland to be a conditional renewal tissue of very low turnover (9, 10). Values for abnormal cell proliferation can now be compared for the first time with normal values obtained by the same method, and we report the application of this method to parathyroid adenomas and to presumably suppressed nonadenomatous tissue in the same glands. We found significant differences, but also substantial overlap, among the three types of tissue. We discuss the results in relation to concepts of parathyroid tumor pathogenesis in general and the set-point hypothesis in particular (2, 3, 4, 5).


    Subjects and Methods
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Patients

We studied 55 patients with primary hyperparathyroidism due to a single adenoma. Eighteen patients (group A) were selected because they had been under the care of one of the authors (A.M.P.) between 1972 and 1980, and detailed records were available. Thirty-seven patients (group B) were selected because fresh parathyroid tissue had been harvested between 1992 and 1995 for the study of cell proliferation by bromodeoxyuridine incorporation, a method subsequently found to be unsatisfactory. Demographic and biochemical data in the two groups are compared in Table 1Go. In group B, the mean age was higher, and there were relatively more male and fewer black patients, but these differences were not significant. The mean plasma calcium level was lower in group B; this might have reflected a change in case-finding methods or in criteria for surgical referral, but the ranges were similar. Also, because of a change in method, the reference range was lower than that during the earlier period. Mean plasma phosphate and creatinine levels did not differ between the groups. In group B, the mean intact PTH level (11) was 126 (SD = 91) pg/mL, with reference values of 10–58. PTH was not measured in most patients in group A. In group B, mean total alkaline phosphatase, measured by automated analysis (12), was 117 (SD = 46) IU/L, with reference values of 27–83. In many patients in group A, alkaline phosphatase had been measured only by the Bodansky method.


View this table:
[in this window]
[in a new window]
 
Table 1. Primary hyperparathyroidism: patient data

 
Histologic procedures

Paraffin-embedded blocks were retrieved, and new sections of 5 µm thickness were cut; one was stained with hematoxylin and eosin, and the others were used for either proliferating cell nuclear antigen (PCNA) (7, 13) or Ki-67 (7, 8, 14) immunohistochemistry. After deparaffinization, the slides were incubated for 5 min in 3% hydrogen peroxide to block endogenous peroxidase. For PCNA, the slides were rinsed in phosphate-buffered saline, covered with 5% horse serum for 40 min, and incubated for 14–16 h overnight at 4 C with a 1:1500 dilution of monoclonal antibody to PCNA (DACO clone PC10). For Ki-67, the slides were transferred to plastic Coplin jars filled with 10 mmol/L citrate buffer (pH 6.0) and heated in a microwave oven twice for 5 min each time at a power of 1080 watts. After cooling at room temperature for 15 min, the slides were covered with 5% horse serum for 40 min and incubated overnight at 4 C with 1:100 MIB-1 monoclonal antibody (Immunotech, Westbrook, ME; catalogue no. 0505). For both PCNA and Ki-67, the slides were treated with biotinylated horse antimouse IgG for 30 min, followed by incubation with peroxidase-conjugated streptavidin for 60 min. Finally, the slides were developed for 5 min with 3-amino-9-ethyl carbazole (Sigma Chemical Co., St. Louis, MO). The mean specimen age was 21.8 yr for group A and 1.9 yr for group B. In each batch, new sections of human tonsil were used as a positive control (8). The sections were derived from two different blocks that had been treated in exactly the same way and had a mean specimen age of 2.0 yr.

Microscopic procedures

In each section, the gland profile was divided whenever possible into adenoma and nonadenoma tissue, using standard criteria (15). Each tissue type was subdivided into 2, 3, or 4 regions depending on size. In the adenomas, at least 20 fields were selected by systematic random sampling (16) at x40 magnification. Using an eyepiece graticule with an unbiased square counting frame with 100 test points, the number of positive cells was counted in 1 large square (=100 small squares) and the total number of chief cells was counted in 1 small square at x200 magnification. All cell profiles with any portion inside the frame, provided they did not touch or intersect the exclusion edges or their extensions, were counted (16). Only strongly staining chief cell nuclei without cytoplasmic staining were considered positive cells. In some cases, total chief cells were counted in the corresponding field of the adjacent hematoxylin- and eosin-stained section. The procedure was continued in each case until at least 150 total chief cells had been counted in small squares, corresponding to 15,000 cell profiles in the large squares. If no positive cell was found, a value of 0.5, equivalent to half the detection limit, was assigned (4). Results were expressed as the labeling index (LI) = positive cells/10,000 cells.

In 10 cases, all from group B, not differing in any feature from the other 27 cases, the entire adenoma profile in Ki-67-stained sections was examined. By systematically moving the stage row by row, the eyepiece graticule and counting frame were superimposed successively on adjacent square fields. In each counting frame, both total and positive cells were recorded as previously described, and the distribution of positive cells in the entire tumor was reconstructed (8). At the periphery of the tumor profile, fields in which fewer than 50 of the small squares overlay the tissue section were disregarded. The reconstructed map of the section was divided into outer and inner regions (8).

Calculation of cell birth rate and life span

For reasons given below, only Ki-67 data were used for these calculations. The Ki-67 antigen is expressed in all stages of the cell cycle, but decays rapidly, with a half-life of less than 1 h and so becomes undetectable very soon after the completion of mitosis (6). The fraction of Ki-67-positive cells is the same as the average fraction of time that each cell spends in the cycling, rather than in the noncycling (G0), state (17). The duration of the cell cycle in the parathyroid gland has never been measured, but a representative mean value for nonneoplastic cells in a variety of tissues and species is 24 h; the majority of values fall between 18–32 hs (9, 10). With this assumption: mean cell birth rate (%/yr) = LI (/10,000) x 365/10,000 x 100 = LI x 3.65. If the current cell birth rate were to be maintained, the corresponding mean cell life span (years) would be 100/(LI x 3.65). For such growth-related variables and for gland weight, the geometric mean was calculated as exp (mean loge x), and the geometric (multiplicative) SD was calculated as exp (SD loge x).

Statistics

Differences between tissue types were evaluated initially by one-way ANOVA, followed by appropriate pairwise comparison, and differences between groups and regions were determined by unpaired or paired Student’s t tests as appropriate. Relations between variables were tested by linear regression analysis. Nonparametric methods were used when indicated. The frequency distribution of positive cells among different graticule fields was compared with the expected Poisson distribution by computation of the {chi}2 value (18).


    Results
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
The primary data are given in Table 2Go. The LI was significantly higher for PCNA than for Ki-67 (P = 0.002), although there was a significant correlation between the two measurements (r = 0.53; P < 0.001). Because positive and negative cells are more easily distinguished and for other reasons described below, further analysis was restricted to the Ki-67 results. The Ki-67 LI was significantly lower in group A than in group B adenomas, presumably because loss of antigen during prolonged storage of the blocks was refractory to microwave retrieval. For the entire series, there was a significant regression of LI on specimen age (Ln LI = 1.00 - 0.0457 x specimen age; r = -0.32; P = 0.017), and this regression was used to correct all LI values to a specimen age of zero (corrected Ln LI = observed Ln LI + 0.0457 x specimen age). In nonadenomatous tissue, there was no difference in Ki-67 LI between group A and group B and no significant regression on specimen age. This difference might reflect smaller sample size or stronger expression in normal than in abnormal tissue and consequent lesser susceptibility to decay with time. The age-corrected LI was almost 4 times higher in the adenomas than in the nonadenomatous tissue, and there was no significant correlation between the LI values.


View this table:
[in this window]
[in a new window]
 
Table 2. Primary hyperparathyroidism: tumor and label data

 
Because of similar clinical and biochemical characteristics and almost identical mean values for gland weight, the groups were combined. There was no significant correlation between corrected log LI, and patient age, total gland weight, or total plasma calcium. The results were the same for analysis restricted to group B, and there was no correlation with PTH. The specimen age-corrected values were used for calculation of cell birth rate and cell life span, and these values are compared with those in nonadenomatous tissue and in normal parathyroid tissue (8) in Table 3Go. There were significant differences among the three types of tissue. The cell birth rate was about twice normal in the adenomas and about half normal in the nonadenomatous tissue. The rates conformed to a log normal distribution with very wide ranges and substantial overlap (Fig. 1Go). Only nine adenomas had values above the 95% confidence interval for the normal glands (expected number, 1.4), and only 16 (29%) had values above the corresponding range. Only one nonadenomatous value was below the 95% confidence interval for the normal glands, and only three were below the corresponding range.


View this table:
[in this window]
[in a new window]
 
Table 3. Primary hyperparathyroidism: cell kinetics

 


View larger version (13K):
[in this window]
[in a new window]
 
Figure 1. Individual values for cell birth rate in three types of parathyroid tissue, plotted on a logarithmic scale. Horizontal lines identify geometric means and ranges corresponding to two multiplicative SD (values in parentheses) on either side of the mean.

 
Results in the 10 cases in which maps of the entire tumor were reconstructed are given in Table 4Go. A total of 473 Ki-67-positive cells were found in approximately 1,243,000 total chief cells. The Ki-67 LI and calculated cell birth rate were significantly higher by about 2-fold in the peripheral than in the central regions, in which the rates did not differ significantly from normal. The frequency distribution of number of positive cells per field showed significantly more fields than expected with no labeled cells, or more than two labeled cells (Table 5Go). The values for the entire tumor did not differ from the values previously obtained by the less rigorous method and were very similar to the values for the whole series based on random sampling, although the variability was lower because of greater precision. The mean number of cell profiles per graticule field in different subjects ranged from 399-1702; the mean of 905 was not significantly different from the value of 1178 cells/graticule field in normal glands (8), but the variability between fields and between subjects was greater. If, in each case, only the fields with the most positive cells had been counted, the arithmetic mean label index would have been 29.4 instead of 3.6/10,000 cells, an 8-fold overestimation. If x400 rather than x200 magnification had been used, the referent cell number would have been reduced 4-fold, and the bias would have been increased an additional 4-fold.


View this table:
[in this window]
[in a new window]
 
Table 4. Parathyroid adenomas: regional differences

 

View this table:
[in this window]
[in a new window]
 
Table 5. Distribution of labeled cells

 

    Discussion
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
For many years, the standard method for studying cell proliferation was based on the uptake of tritiated thymidine by cells in S phase. This method was the first to be applied to the parathyroid gland (19), but is cumbersome and requires great care to ensure cell viability during the incubation of freshly harvested tissue; the same disadvantages apply to the use of bromodeoxyuridine as an S phase marker (20). Less technically demanding are methods based on information already present in the nucleus, obviating the need for administration of an exogenous label. The most widely used has been the mitotic karyotype (21), but because of the very short duration of mitosis, positive cells are extremely infrequent in low turnover tissues (4). Several new cell cycle markers with advantages over the mitotic karyotype have been developed (7, 20, 22), of which PCNA has been most often applied to the parathyroid gland (23, 24, 25). Unfortunately, PCNA expression overestimates the proportion of cycling cells. Because of its long half-life, it is detectable for a considerable time after completion of mitosis (7), and it is expressed during DNA repair as well as during cell division (7, 26). We found the proportion of PCNA-positive cells to be about double the proportion of Ki-67-positive cells, based on median values. An even greater difference of about 3-fold has previously been reported in abnormal parathyroid tissue (24).

The prevalence of cell cycle markers has usually been used as a diagnostic and prognostic tool in patients with neoplasia (7, 20, 21, 22) and much less often to study rates of cell proliferation. Until recently, it was standard practice in diagnostic histopathology to express the prevalence of cell cycle markers per high power field, but because the areal density of cell profiles is so variable, it is much more satisfactory to use a defined number of cell profiles as the referent (27); in the present study, the number of cells per graticule field varied over more than a 4-fold range between patients. The interpretation of data concerning cell cycle markers depends heavily on the method of sampling within the section. In diagnostic work it has been usual to make measurements only in the most heavily labeled regions of the section (20). In the present study, this procedure would have overestimated the proportion of labeled cells and the calculated cell birth rate by at least 8-fold, and possibly much more, depending on the magnification used (8). We avoided this bias and estimated even very low prevalence values without unreasonable expenditure of time by using a much smaller graticule area to estimate the referent cell profile number than to count the positive cells (16).

The calculation of cell birth rate and life span assumed a duration of Ki-67 expression of 24 h, an assumption previously justified in detail (28). If the duration of expression is shorter, the calculated cell birth rate would be higher and vice versa. The duration of the cell cycle is generally longer in malignant tumors than in normal tissue (10). If this applied also to parathyroid adenomas, the difference in cell birth rate would be even smaller than we have calculated. In previous work, the geometric mean rate of cell proliferation was estimated to be 13.7%/yr in sporadic parathyroid adenomas, assuming the duration of S phase to be 12 h (3), and 6.4%/yr in radiation-associated parathyroid adenomas, assuming the duration of mitosis to be 0.5 h (4). Thus, three independent methods, all using an appropriate sampling procedure, have produced results that varied over little more than a 2-fold range. Considering the uncertainties in the estimates of the durations of various subdivisions of the cell cycle, this is reasonable agreement. Fresh tissue (3) may have given higher results than archival tissue (4) (Table 4Go) because of unrecognized changes during tissue processing and storage. It is also possible that the rates are indeed somewhat lower in radiation-associated than in sporadic adenomas (4), and that such tumors are closer to their growth asymptote (5).

The proportion of Ki-67-positive cells was approximately 50 times smaller in the present study than in studies that used selective and consequently biased sampling (Table 6Go) (29, 30). The similarity in LI results when the whole section was examined (2.89 vs. 2.72) demonstrates that our sampling was unbiased. We believe that our detection method has been well validated (8, 28) and that the absence of sampling bias is the most likely explanation for our lower results. Very high results despite less biased (although nonrandom) sampling probably reflect an unusually sensitive method for PCNA that detected more cells undergoing DNA repair (25). Even higher values for the proportion of cycling cells are given by flow cytometry (Table 6Go) (31), but this method is not applicable to low turnover tissue, partly because of cellular debris (32) and partly because of inability to distinguish between the elective tetraploidy of cells that have completed S phase and constitutive tetraploidy. This is a feature of many normal tissues (2) and of tumors of several endocrine glands, including the parathyroid (33, 34).


View this table:
[in this window]
[in a new window]
 
Table 6. Cell proliferation in PT adenomas: comparison of methods

 
One of the traditional histological criteria for parathyroid adenoma is an adjacent rim of normal or more strictly nonadenomatous tissue (15). Based on physiological reasoning and ultrastructural features suggesting inhibition of PTH secretion (35), such tissue is generally assumed to be suppressed with respect to its secretory activity. Consistent with this conclusion, the secretory set-point determined in vitro in cells harvested from other glands is reduced below normal (36). We have demonstrated that nonadenomatous tissue is suppressed with respect to its proliferative as well as its secretory activity, confirming a recent report (25). This is a further example of the close link between these two aspects of parathyroid cell function (2), a link that is probably characteristic of all endocrine glands (37). A reduction in cell birth rate by 50% together with the persistence of apoptosis at the same rate would explain the small, but significant, reduction in the weight of nonadenomatous glands in patients with parathyroid adenoma (38, 39).

We found a significantly higher proportion of cycling cells in the peripheral than in the central regions of parathyroid adenomas and a significant deviation from random distribution. By contrast, in normal parathyroid glands, there is no difference between peripheral and central regions and close conformity to a Poisson distribution (8). A clustered distribution of cycling cells has been reported in nodular secondary hyperparathyroidism and also in some parathyroid adenomas (24), although this conclusion was based on simple inspection of the sections rather than on statistical evaluation. We did not find such clusters (indeed, the largest number of cycling cells in any graticule field was six), but, rather, observed a general tendency for cell birth rate to be higher closer to the perimeter of the tumors. In a large, rapidly growing, malignant tumor, the central region may be relatively ischemic and hypoxic (40), but there is no reason to suppose that blood supply would be compromised in the center of a small, slowly growing, benign tumor of a highly vascular tissue (41), and there was no histological evidence for such a phenomenon. A differential cell birth rate appears to be a characteristic of parathyroid tumor growth, for which an explanation is required.

It was previously demonstrated (3, 4) that cell birth rates in parathyroid adenomas had declined substantially during their life span, assuming that they arose from a single mutant cell. In radiation-associated adenomas, the initial cell birth rate can be estimated by fitting the data to the Gompertz function (5). The geometric mean and 95% confidence limits of these estimated rates are compared with observed rates at the time of excision in Table 7Go. For this purpose, data in the 10 completely mapped cases were used, because the precision of individual values was greater and the range narrower. The estimated decline in cell birth rate, based on geometric means, was 20- to 25-fold, but the ranges were very wide, so that the extent of decline could have varied substantially between cases. Because of the differential cell birth rate previously discussed (Table 4Go), the decline had been greater in the center than in the periphery of the tumor. Tumors enlarge mainly by interstitial growth, a process that must be accompanied by cell displacement, but it is reasonable to assume that the mean age of cells is greater in the center than in the periphery, which suggests that the magnitude of decline in cell birth rate in parathyroid adenomas is a function of cell age.


View this table:
[in this window]
[in a new window]
 
Table 7. Current and initial cell birth rates in parathyroid adenomas

 
The preceding argument highlights a central paradox in the pathogenesis of parathyroid adenomas. The prevailing paradigm of neoplasia is that abnormal cells accumulate a succession of mutations, each of which confers an additional growth advantage, a process known as clonal evolution (2, 42). This paradigm is widely believed to apply to endocrine tumors in general and to parathyroid adenomas in particular (43, 44). A high proportion of these tumors harbor at least one of a large number of different mutations, including activation of the putative protooncogene cyclin D1 (45), and allelic losses at multiple sites, each consistent with the loss or inactivation of a different tumor suppressor gene (44). However, during a process that supposedly leads to a progressive increase in the rate of cell division, the rate is progressively declining. Furthermore, the cells that have had the longest time to accumulate mutations have the lowest rate of cell division, a rate that is no longer significantly greater than normal. Another difficulty (2) is to reconcile the frequent occurrence of mutations with rates of cell division that are at least 10 times lower than those in meningiomas, the only other benign tumors for which adequate data are available (4), and up to 1000 times lower than those in malignant tumors (10).

One way out of this dilemma, the only way in our opinion, is provided by the set-point hypothesis. It is proposed (2, 3, 4, 5, 8, 46) that a hereditary change in phenotype occurs in a single cell that decreases its sensitivity to its ambient calcium concentration. This change does not result from a mutant form of the serpentine calcium sensing receptor (47, 48), but could result from a reduction in the number of normal receptors (49), which is the main determinant of the secretory set-point (50). By whatever means the change in sensitivity was brought about, the abnormal cell would behave in the same way as a normal cell exposed to hypocalcemia. It would increase its rate of PTH secretion, but to no avail, and eventually would be driven to divide. The clone of new cells would continue to proliferate, but ever more slowly, until it was large enough to raise the patient’s plasma calcium level to the new secretory set-point. Because of the very long time interval between successive divisions, the decline in cell birth rate would be very slow and would have progressed further in older cells (Table 4Go). The increase in cell proliferation in the early stages of tumor growth would increase the mutagenic risk (51), and so set the stage for the mutations that have been detected. Although not yet supported by direct evidence, the set-point hypothesis accounts for the current clinical characteristics of primary hyperparathyroidism, the main abnormality in PTH secretion, the low rates of cell proliferation at the time of surgical excision, the difference in cell birth rate between the central and peripheral regions, the inferred pattern of asymptotic growth, and the high prevalence of mutations, all by means of a single mechanism.


    Acknowledgments
 
We thank Gary Talpos for provision of fresh parathyroid tissue, Richard Zarbo for access to archival specimens, Raouf Nakhleh for assistance with immunohistological methods, Paula Dillon for section preparation, Paula Roberson for assistance with statistical analysis, and Constance Mott for preparation of the manuscript.


    Footnotes
 
1 This work was supported by NIH Grant PO1-AG/AR-13918 and the Breech Endowment of the Bone and Joint Center, Henry Ford Hospital. Back

Received February 4, 1997.

Revised September 4, 1997.

Revised November 24, 1997.

Accepted December 4, 1997.


    References
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Parfitt AM, Rao DS, Kleerekoper M. 1991 Asymptomatic primary hyperpara-thyroidism discovered by multi-channel biochemical screening. Clinical course and considerations bearing on the need for surgical intervention. J Bone Miner Res. 6:S97–S101.
  2. Parfitt AM. 1994 Parathyroid growth: normal and abnormal. In: Bilezikian JP, ed. The parathyroids—basic and clinical concepts. New York: Raven Press; 373–405.
  3. Parfitt AM, Willgoss D, Jacobi J, Lloyd HM. 1991 Cell kinetics in parathyroid adenomas: evidence for decline in rates of cell birth and tumour growth, assuming clonal origin. Clin Endocrinol (Oxf). 35:151–157.[Medline]
  4. Parfitt AM, Braunstein GD, Katz A. 1993 Radiation-associated hyperparathyroidism: comparison of adenoma growth rates, inferred from weight and duration of latency, with prevalence of mitosis. J Clin Endocrinol Metab. 77:1318–1322.[Abstract]
  5. Parfitt AM, Fyhrie DP. Gompertzian growth curves in parathyroid tumors: further evidence for the set point hypothesis. Cell Prolif. In press.
  6. Duchrow M, Gerdes J, Schluter C. 1994 The proliferation-associated Ki-67 protein: definition in molecular terms. Cell Prolif. 27:235–242.[Medline]
  7. Yu CC-W, Filipe MI. 1993 Update on proliferation-associated antibodies applicable to formalin-fixed paraffin-embedded tissue and their clinical applications. Histochem J. 25:843–953.[Medline]
  8. Wang Q, Palnitkar S, Parfitt AM. 1997 The basal rate of cell proliferation in normal human parathyroid tissue: implications for the pathogenesis of hyperparathyroidism. Clin Endocrinol (Oxf). 46:343–349.[CrossRef][Medline]
  9. Wright N, Alison M, eds. 1984 The biology of epithelial cell populations. Oxford: Clarendon Press.
  10. Baserga R. 1985 The biology of cell reproduction. Cambridge: Harvard University Press.
  11. Nussbaum SR, Potts Jr JT. 1991 Immunoassays for parathyroid hormone 1–84 in the diagnosis of hyperparathyroidism. J Bone Miner Res. 6(Suppl 2):S43–S50.
  12. Parfitt AM, Podenphant J, Villanueva AR, Frame B. 1985 Metabolic bone disease with and without osteomalacia after intestinal bypass surgery: a bone histomorphometric study. Bone. 6:211–220.[Medline]
  13. Amin MB, Ma CK, Linden MD, Kubus JJ, Zarbo RJ. 1993 Prognostic value of proliferating cell nuclear antigen index in gastric stromal tumors. Am J Clin Pathol. 100:428–432.[Medline]
  14. McCormick D, Chong H, Hobbs C, Datta C, Hall PA. 1993 Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB-1. Histopathology. 22:355–360.[Medline]
  15. LiVolsi VA. 1994 Embryology, anatomy, and pathology of the parathyroids. In: Bilezikian JP, ed. The parathyroids—basic and clinical concepts. New York: Raven Press; 1–14.
  16. Gundersen HJG, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K, Myengaard JR, Pakkenberg B, Sorensen FB, Vesterby A, West MJ. 1988 Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS. 96:379–394.[Medline]
  17. Kroll S, Char D, Kaleta-Michaels S. 1995 A stochastic model for dual label experiments: an analysis of the heterogeneity of S phase duration. Cell Prolif. 28:545–567.[Medline]
  18. Colton T. 1974 Statistics in medicine. Boston: Little, Brown.
  19. Lloyd HM, Jacobi JM, Willgoss D, Kearney J, Ward P. 1981 DNA synthesis and secretory activity in parathyroid adenomas. Acta Endocrinol (Copenh). 96:70–74.[Abstract/Free Full Text]
  20. Carroll PR, Waldman FM, Rosenau W, Cohen MB, Vapnek JM, Fong P, Narayan P, Mayall BH. 1993 Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression. J Urol. 149:403–407.[Medline]
  21. Baak JPA. 1990 Mitosis counting in tumors. Hum Pathol. 21:683–685.[CrossRef][Medline]
  22. Pelosi G, Zamboni G. 1996 Proliferation markers and their uses in the study of endocrine tumors. Endocr Pathol. 7:103–119.[Medline]
  23. Kurimoto S, Moriyama N, Nagase Y, Doi N, Aso Y. 1993 Expression of proliferating cell nuclear antigen (PCNA) in human parathyroid adenoma. Acta Histochem Cytochem. 26:391–396.
  24. Loda M, Lipman J, Cukor B, Bur M, Kwan P, DeLellis RA. 1994 Nodular foci in parathyroid adenomas and hyperplasias: an immunohistochemical analysis of proliferative activity. Hum Pathol. 25:1050–1056.[CrossRef][Medline]
  25. Yamaguchi S, Yachiku S, Morikawa M. 1997 Analysis of proliferative activity of the parathyroid glands using proliferating cell nuclear antigen in patients with hyperparathyroidism. J Clin Endocrinol Metab. 82:2681–2688.[Abstract/Free Full Text]
  26. Shivil KK, Kenny MK, Wood RD. 1992 Proliferating cell nuclear antigen is required for DNA excision repair. Cell;69 :367–374.
  27. Quinn CM, Wright NA. 1990 The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol. 160:93–102.[CrossRef][Medline]
  28. Wang Q, Palnitkar S, Parfitt AM. 1996 Parathyroid cell proliferation in the rat. Effect of age and of phosphate administration and recovery. Endocrinology. 137:4558–4562.[Abstract]
  29. Abbona GC, Papotti M, Gasparri G, Bussolati G. 1995 Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining. Hum Pathol. 26:135–138.[CrossRef][Medline]
  30. Lloyd RV, Carney JA, Ferreiro JA, et al. 1995 Immunohistochemical analysis of the cell cycle-associated antigens K-67 and retinoblastoma protein in parathyroid carcinomas and adenomas. Endocr Pathol. 6:279–287.[Medline]
  31. Chryssochoos JT, Weber CJ, Cohen C, et al. 1995 DNA index and ploidy distinguish normal human parathyroids from parathyroid adenomas and primary hyperplastic parathyroids. Surgery. 118:1041–1050.[Medline]
  32. Meyer JS, Coplin MD. 1988 Thymidine labeling index, flow cytometric S-phase measurement, and DNA index in human tumors. Am J Clin Pathol. 89:586–595.[Medline]
  33. Joensuu H, Klemi PJ. 1988 DNA aneuploidy in adenomas of endocrine organs. Am J Pathol. 132:145–151.[Abstract]
  34. Bengtsson A, Grimelius L, Johansson H, Ponten J. 1977 Nuclear DNA-content of parathyroid cells in adenomas, hyperplastic and normal glands. APMIS. 85:455–460.
  35. Wernerson A, Svensson O, Reinholt FP. 1995 Quantitative and three-dimensional aspects of the rat parathyroid gland in normo-, hypo-, and hypercalcemia. Microsc Res Technol. 32:129–147.[CrossRef][Medline]
  36. Brown EM, Wilson RE, Thatcher JG. 1981 Abnormal calcium-regulated PTH release in normal parathyroid tissue from patients with adenoma. Am J Med. 71:565–570.[CrossRef][Medline]
  37. Lloyd HM, Jacobi JM, Willgoss DA. 1995 DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine. Clin Endocrinol (Oxf). 43:79–85.[Medline]
  38. Ejerblad S, Grimelius L, Johansson H, Werner I. 1976 Studies on the non-adenomatous glands in patients with a solitary parathyroid adenoma. Ups J Med Sci. 81:31–36.[Medline]
  39. Parfitt AM. 1982 Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab. 8:92–119.[Medline]
  40. Sutherland RM. 1986 Importance of critical metabolites and cellular interactions in the biology of microregions of tumors. Cancer. 58:1668–1680.[CrossRef][Medline]
  41. Murakami T, Tanaka T, Taguchi T, Ohtsuka A, Kikuta A. 1995 Blood vascular bed and pericapillary space in rat parathyroid glands. Microsc Res Technol. 32:112–119.[Medline]
  42. Knudson AG. 1995 Mutation and cancer: a personal odyssey. Adv Cancer Res. 67:1–23.[Medline]
  43. Arnold A. 1994 Molecular mechanisms of parathyroid neoplasia. Endocrinol Metab Clin North Am. 23:93–107.[Medline]
  44. Tahara H, Smith AP, Gaz RD, Cryns VL, Arnold A. 1996 Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Cancer Res. 56:599–605.[Abstract/Free Full Text]
  45. Hsi ED, Zukerberg R, Yang W-I, Arnold A. 1996 Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab. 81:1736–1739.[Abstract]
  46. Mallette LE. 1991 The parathyroid polyhormones: new concepts in the spectrum of peptide hormone action. Endocr Rev. 12:110–117.[CrossRef][Medline]
  47. Hosokawa Y, Pollak MR, Brown EM, Arnold A. 1995 Mutational analysis of the extracellular Ca2+-sensing receptor gene in human parathyroid tumors. J Clin Endocrinol Metab. 80:3107–3110.[Abstract]
  48. Thompson DB, Samowitz WS, Odelberg S, Davis RK, Szabo J, Heath III H. 1995 Genetic abnormalities in sporadic parathyroid adenomas: loss of heterozygosity for chromosome 3q markers flanking the calcium receptor locus. J Clin Endocrinol Metab. 80:3377–3380.[Abstract]
  49. Kifor O, Moore FD, Wang P, et al. 1996 Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab. 81:1598–1606.[Abstract]
  50. Ho C, Conner DA, Pollak MR, et al. 1995 A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet. 11:389–394.[CrossRef][Medline]
  51. Cohen SM. 1995 Role of cell proliferation in regenerative and neoplastic disease. Toxicol Lett. 82/83:15–21.



This article has been cited by other articles:


Home page
JAMAHome page
G. J. Strewler
A 64-Year-Old Woman With Primary Hyperparathyroidism
JAMA, April 13, 2005; 293(14): 1772 - 1779.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Garcia de la Torre, I. Buley, J. A. H. Wass, D. G. Jackson, and H. E. Turner
Angiogenesis and Lymphangiogenesis in Parathyroid Proliferative Lesions
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2890 - 2896.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. M. Mallya, J. J. Gallagher, and A. Arnold
Analysis of Microsatellite Instability in Sporadic Parathyroid Adenomas
J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1248 - 1251.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. S. Rao, M. Honasoge, G. W. Divine, E. R. Phillips, M. W. Lee, M. R. Ansari, G. B. Talpos, and A. M. Parfitt
Effect of Vitamin D Nutrition on Parathyroid Adenoma Weight: Pathogenetic and Clinical Implications
J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1054 - 1058.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parfitt, A. M.
Right arrow Articles by Palnitkar, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parfitt, A. M.
Right arrow Articles by Palnitkar, S.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals